Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JS1K | ISIN: IE00B4Q5ZN47 | Ticker-Symbol: J7Z
Tradegate
04.07.25 | 11:23
91,94 Euro
-0,07 % -0,06
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
JAZZ PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
91,8092,1819:02
91,7692,2204.07.

Aktuelle News zur JAZZ PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiEC approves Jazz Pharmaceuticals' Ziihera for biliary tract cancer3
DiJazz Pharmaceuticals gets EU nod for Ziihera4
JAZZ PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiJazz Pharma Says EU Grants Conditional MA To Ziihera For Advanced HER2-Positive Biliary Tract Cancer1
12.06.Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®15
10.06.Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca8
10.06.Jazz Pharma Says FDA Granted Priority Review For Zepzelca And Tecentriq Combo For ES-SCLC3
10.06.Jazz Pharmaceuticals plc: Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer115Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically...
► Artikel lesen
10.06.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 202572First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium...
► Artikel lesen
05.06.Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ)1
03.06.Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study2
03.06.UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data1
03.06.UBS behält Kaufempfehlung für Jazz Pharmaceuticals nach positiven Studiendaten bei5
03.06.The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts3
03.06.Roche/Jazz Pharmaceuticals share positive phase 3 results for lung cancer combination therapy6
02.06.Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment2
02.06.Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera2
02.06.Jazz Pharmaceuticals berichtet über vielversprechende Ergebnisse der Phase-2-Studie für Ziihera2
02.06.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ...74Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up...
► Artikel lesen
21.05.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences256DUBLIN, May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies...
► Artikel lesen
14.05.Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock2
Weiter >>
86 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1